These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23425867)

  • 1. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
    Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
    Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
    Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
    Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
    Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
    Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
    Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
    Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
    J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
    Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
    Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Distinction between benign and malignant pheochromocytomas].
    Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
    Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
    Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
    Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
    Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
    Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in pheochromocytoma.
    Clarke MR; Weyant RJ; Watson CG; Carty SE
    Hum Pathol; 1998 May; 29(5):522-6. PubMed ID: 9596278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytomas, PASS, and immunohistochemistry.
    Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
    Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.